A trio of new pivotal trial entries
AstraZeneca and Lilly put PARP1 and KRAS G12C inhibitors into their first phase 3s, while Amgen advances DLL3 into early-stage disease.
A changing of the guard in stomach cancer?
Akeso’s cadonilimab hits in its first-line study, but there’s no US data and no US partner.
ESMO 2023 – sabestomig has it all to do in TIM-3
Astra manages to avoid the toxicities that scuppered Lilly’s PD-1 x TIM-3 contender, but still needs to dial up sabestomig’s efficacy.
ESMO 2023 – Amgen’s Steap1 project spurs cautious optimism
But toxicity will be closely watched in future trials.
ESMO 2023 – tarlatamab hits the target for Amgen
But late-breaking data raise questions about lack of a dose response.
